Molecular Markers of Depressive Disorder (DD) and their clinical use
DOI:
https://doi.org/10.60104/revhugv13465Keywords:
Genomic Medicine, Molecular Marker, Depressive Disorder, DepressionAbstract
Introduction: Depressive disorder (DD) is one of the most prevalent disorders in Brazil, it is characterized as an affective disorder whose symptoms include depressive mood, insecurity, distorted view of reality that may or may not be accompanied by psychotic symptoms. The diagnosis for TD is complex and involves several variables, such as environmental, biological and psychosocial. In view of this, the search for molecular markers that can contribute to the diagnoses and prognoses of patients with depressive disorder can help the doctor's therapeutic approach. Methodology: This is an integrative review of the literature, allowing the analysis of the scientific bibliography on molecular markers of Depressive Disorder in the general population available between 2010-2022 in a systematic and expanded manner. Objectives: The objective of the research is to review the publications available in the literature on the molecular and genetic analysis of Depressive Disorder. Result: The survey of molecular markers is extremely important to enable easier diagnosis and more effective treatment, which is personalized for each situation. Markers such as cortisol, p11, BRAF and interleukin have shown to be promising markers for the diagnosis and/or prognosis of depressive disorder. Conclusion: Molecular markers are extremely important for early detection and choosing the best treatment for each individual. In this way, the markers found, for the most part, can be obtained through blood or saliva tests, which generates less costs for the Unified Health System (SUS), optimizing diagnosis and guaranteeing access to diagnosis and treatment in a more efficient way. assertive.
Downloads
References
Góes, AC; Oliveira, BV. Projeto Genoma Humano: um retrato da construção do conhecimento científico sob a ótica da revista Ciência Hoje. Ciência & Educação (Bauru), setembro de 2014. 20 (3): 561–577. https://doi.org/10.1590/1516-73132014000300004
Porto, G. Medicina Personalizada. Biotec AHG. 2015
Stopa, SR, Malta DC, Oliveira MM, Lopes CS, Menezes PS, Kinoshita RT, et al . Prevalência do autorrelato de depressão no Brasil: resultados da Pesquisa Nacional de Saúde, 2013. Revista Brasileira de Epidemiologia [online]. 2015, 18 (170-180). https://doi.org/10.1590/1980-5497201500060015
Miller, DB, O'Callaghan, JP. Personalized medicine in major depressive disorder - opportunities and pitfalls. Metabolism: clinical and experimental, 62 (01), S34–S39. https://doi.org/10.1016/j.metabol.2012.08.021
Quevedo, J, Silva, AG. Depressão: teoria e clínica. Porto Alegre: Artmed, 2013.
Lopez, JP, Kos, A., & Turecki, G. Depressão maior e seu tratamento. Opinião atual em psiquiatria. 2018. https://doi.org/10.1097/yco.0000000000000379
Bomfim, AM; Carneiro, GLS ; Michels, MS. Impactos do Isolamento Social Durante a Pademia de COVID-19 na Saúde Mental - Uma Revisão Sistemática. Psicólogo informação, 24(24). 5–13, 2022.
Targum, SD, Schappi, J., Koutsouris, A. et al. A novel peripheral biomarker for depression and antidepressant response. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-021-01399-1
Binder E.; Salyakira D.; Lichtner, P; Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36(1). 2004. https://doi.org/10.1038/ng1479
Zhang, X, Gainetdinov, RR, Beaulieu, JM, et al. Increased Serum Levels of Cortisol and Inflammatory Cytokines in People With Depression. Journal Nerv Ment Dis. 2019. https://doi.org/10.1097/nmd.0000000000000957
Garcia WD.; STROPARO E. Metilação do gene BDNF e sua relação com o transtorno depressivo maior. Revista eletrônica biociências, biotecnologia e saúde, 12 (23). 88–93, 2019.
Mora C; Zonca V; Riva, M A. Blood biomarkers and treatment response in major depression. Expert Review of Molecular Diagnostics. 18 (6). 513-529. 2018. https://doi.org/10.1080/14737159.2018.1470927
Mora C, Zonca V, Riva MA, Cattaneo A. Blood biomarkers and treatment response in major depression. Expert Rev Mol Diagn. Jun. 2018. https://doi.org/10.1080/14737159.2018.1470927
Gadad BS, Jha MK, Czysz AH, Mayes TL, Emslie MP, Trivedi MH. Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2017.07.001
Genesignt. GeneSight DNA Test for Psychiatric & Depression Medication | GeneSight. GeneSight. 2022.
Yonekura T., Takeda K., Shetty V., Yamaguchi M. Relationship between salivary cortisol and depression in adolescent survivors of a major natural disaster. J. Physiol. Sci. 2014; 64:261–267. https://doi.org/10.1007/s12576-014-0315-x
Cui, Y; Zhang, H; Wang S; et al. Stimulated Parotid Saliva Is a Better Method for Depression Prediction. Biomedicines, v. 10, n. 9, p. 2220, 2022. https://doi.org/10.3390/biomedicines10092220
Fan, Hui-min; Sun, Xin-yang; GUO, Wei; et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. Journal of Psychiatric Research, 59 (1): 45–52, 2014. https://doi.org/10.1016/j.jpsychires.2014.08.007
He S; Liu X; Jiang K; et al. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. Journal of Psychiatric Research, 78 (1): 65–71, 2016. https://doi.org/10.1016/j.jpsychires.2016.03.015
Wei, Z; Xie GJ; Mao X; et al. Exosomes from patients with major depression cause depressive-like behaviors in mice with involvement of miR-139-5p-regulated neurogenesis. Neuropsychopharmacology, 45 (6): 1050–1058, 2020. https://doi.org/10.1038/s41386-020-0622-2
Lian, N; Niu O; Lei Y; et al. MiR-221 is involved in depression by regulating Wnt2/CREB/BDNF axis in hippocampal neurons. Cell Cycle. 2745- 2755. 2018. https://doi.org/10.1080/15384101.2018.1556060
Camkurt M; Acar S; Coskun S; et al. Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. Journal of Psychiatric Research, 69(1): 67–71, 2015. https://doi.org/10.1016/j.jpsychires.2015.07.023
Li, Jing; Meng H; Cao W; et al. MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4. Neuroscience Letters, 606 (1): 167–172, 2015. https://doi.org/10.1016/j.neulet.2015.08.038
Issler O; Haramati S; Paul, E; et al. MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy, and Intact Serotonergic Activity. Neuron, 83(2): 344–360, 2014. https://doi.org/10.1016/j.neuron.2014.05.042
Silva, AP; Fujimura, PT; Silva, JR; et al. Brain-enriched MicroRNA-184 is downregulated in older adults with major depressive disorder: A translational study. Journal of Psychiatric Research, 111 (1): 110–120, 2019. https://doi.org/10.1016/j.jpsychires.2019.01.019
Sun, N; Lei L; Wang Y; et al. Preliminary comparison of plasma notch-associated microRNA-34b and -34c levels in drug naive, first episode depressed patients and healthy controls. Journal of Affective Disorders, 194 (1): 109–114, 2016. https://doi.org/10.1016/j.jad.2016.01.017
Belzeaux, R; Bergon, A; Jeanjena V; et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Translational Psychiatry, 2 (11) 2012. https://doi.org/10.1038/tp.2012.112
Azevedo JA.; Carter BS.; Meng F; et al. The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. Journal of Psychiatric Research, 82 (1): 58–67, 2016. https://doi.org/10.1016/j.jpsychires.2016.07.012
Smalheiser NR.; Lugli, G; Zhang H; et al. Expression of microRNAs and Other Small RNAs in Prefrontal Cortex in Schizophrenia, Bipolar Disorder and Depressed Subjects. Plos One (1). 2014. https://doi.org/10.1371/journal.pone.0086469
Kuang WH; Dong, ZQ; Tian LT; et al. MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment. Brazilian Journal of Medical and Biological Research, 51 (7), 2018. https://doi.org/10.1590/1414-431x20187212
Shi, Y; Wzng Q; Song R; et al. Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers. eBioMedicine, 71 (1): 103569, 2021. https://doi.org/10.1016/j.ebiom.2021.103569
Cho JH; Shu SM.; Mahbod A. Lipopolysaccharide-stimulated intracellular cytokines and depressive symptoms in community-dwelling older adults. Archives of Clinical Psychiatry (São Paulo), 46(5): 137–140, 2019. https://doi.org/10.1590/0101-60830000000212
Zadka L; Dziegiel P; Kulus M; et al. Clinical Phenotype of Depression Affects Interleukin-6 Synthesis. Journal of Interferon & Cytokine Research, 37 (6): 231–245, 2017. https://doi.org/10.1089/jir.2016.0074
Grassi-Oliveira R; Brieztke E.; Teixeira E, Antônio; et al. Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Revista Brasileira de Psiquiatria, 34 (1): 71–75, 2012. https://doi.org/10.1590/S1516-44462012000100013
King DR.; Salako DC.; Arthur B, Samia K; et al. Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample. Journal of Affective Disorders, 281 (1): 384–389, 2020. https://doi.org/10.1016/j.jad.2020.12.050
Jung YE ; Kang KY. Elevated hs-CRP level is associated with depression in younger adults: Results from the Korean National Health and Nutrition Examination Survey (KNHANES 2016). Psychoneuroendocrinology, 109: p. 104397, 2019. https://doi.org/10.1016/j.psyneuen.2019.104397
Cho, SH; Lim, JE; Lee J. Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity. Journal of Affective Disorders, 291: 375–383, 2021. https://doi.org/10.1016/j.jad.2021.05.040
Pitharouli MC; Hagenaars SP; Glanville KP. Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK
Biobank. American Journal of Psychiatry. 178(6): 552-529, 2021. https://doi.org/10.1176/appi.ajp.2020.20060947
Chamberlain SR.; Cavanagh J; De Boer Peter; et al. Treatment-resistant depression and peripheral C-reactive protein. British Journal of Psychiatry, 214 (1): 11–19, 2018. https://doi.org/10.1192/bjp.2018.66
Ghanbarirad M. Mehrdad H, Seyed MS, Ahmad M. Dysregulation of Myt1 expression acts as a potential peripheral biomarker for major depressive disorder and bipolar disorder, Journal of Neurogenetics, 35:4, 381-386, 2021 https://doi.org/10.1080/01677063.2021.1928663
Uint L; Bastos GM; Thrurow HS. Increased levels of plasma IL-1b and BDNF can predict resistant depression patients. Revista da Associação Médica Brasileira,65 (3): p. 361–369, 2019. https://doi.org/10.1590/1806-9282.65.3.361
Alexander B; Warner-Schmid J; Eriksson TM.; et al. Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens. Science Translational Medicine, 2(54), 2010. https://doi.org/10.1126/scitranslmed.3001079
Chen MX; Oh YS ; Kim Y. S100A10 and its binding partners in depression and antidepressant actions. Frontiers in Molecular Neuroscience, 15, 2022. https://doi.org/10.3389/fnmol.2022.953066
Melas PA.; Rogdaki M; Lennartsson A. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. The International Journal of Neuropsychopharmacology. 15(5): 669–679, 2011. https://doi.org/10.1017/S1461145711000940
Ali T, Rahman SU, Hao Q, Li W, Liu Z, Shah FA, et al. Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation. Journal of Pineal Research, 69 (2) 17 jul. 2020. https://doi.org/10.1111/jpi.12667
Won E.; Lee JS.; Young KK. Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression. International Journal of Molecular Sciences, 23(1): 305–305, 28 dez. 2021. https://doi.org/10.3390/ijms23010305
Shokri-Mashhadi L, Darant M, Rouhani MH. Yahay M, Feltham B, Saraf-Bank S. Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials. Behavioural Brain Research, 436: 114083– 114083, 2023. https://doi.org/10.1016/j.bbr.2022.114083
King DR. Salaki DC, Arthur-Bentil S, Rubin AE, Italiya JB, Tan JS, Macris DG, Neely HK et al. Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample. Journal of Affective Disorders, 281 (1): 384–389, 1 fev. 2021 https://doi.org/10.1016/j.jad.2020.12.050
Melin EO, Svensson R, Dereke J, Hillman M. Galectin-3 Binding Protein, Depression, and Younger Age Were Independently Associated With Alexithymia in Adult Patients With Type 1 Diabetes. Frontiers in Psychiatry, 12. 11 maio 2021. https://doi.org/10.3389/fpsyt.2021.672931
